share_log

Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4

Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4

Keybanc以增持评级开始对标准BioTools进行保险,宣布目标股价为4美元
Benzinga ·  2023/07/12 04:29

Keybanc analyst Paul Knight initiates coverage on Standard BioTools (NASDAQ:LAB) with a Overweight rating and announces Price Target of $4.

KeyBanc分析师保罗·奈特在标准生物工具(纳斯达克:LAB)上发起增持评级,并宣布目标价为4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发